What is the importance of using Pneumococcal Conjugate Vaccines in India? 1. These vaccines are effective against pneumonia as well as meningitis and sepsis. 2. Dependence on antibiotics that are not effective against drug resistant bacteria can be reduced. 3. These vaccines have no side effects and cause no allergic reactions. Select the correct answer using the code given below:
Contents13
- A1 only
- B1 and 2 only
- C3 only
- D1, 2 and 3
Show answer
Answer: (B) 1 and 2 only
Pneumococcal Conjugate Vaccines (PCVs) protect against infections caused by the bacteria Streptococcus pneumoniae (pneumococcus).
Let's check each statement:
Statement 1 — CORRECT:
PCVs don't just prevent pneumonia.
They also protect against meningitis (brain infection) and sepsis (blood poisoning).
That's because pneumococcus bacteria can cause all these diseases.
Statement 2 — CORRECT:
Here's the logic — if vaccines prevent bacterial infections, then people won't need antibiotics to treat those infections.
This reduces the overuse and misuse of antibiotics, which is a major cause of Antimicrobial Resistance (AMR).
PCVs can potentially cut antibiotic dependence by nearly 50% per year.
Statement 3 — NOT CORRECT:
The question says PCVs have "no side effects."
This is false.
Like most vaccines, PCVs can cause mild side effects such as fever, loss of appetite, headache, and irritability.
No vaccine is completely free of side effects.
Answer: B (1 and 2 only).
Key Takeaway:
PCVs protect against pneumonia + meningitis + sepsis, AND help fight antibiotic resistance.
But they DO have mild side effects.
Pneumococcal Conjugate Vaccines protect against multiple diseases caused by the same bacteria - pneumonia, meningitis, and sepsis - making them highly cost-effective for public health programs.
India launched PCV in its Universal Immunization Programme around 2017-2019, making this a relevant policy topic for UPSC during this period.
The question tests understanding of vaccine mechanisms and the connection between vaccination and antimicrobial resistance - a major global health challenge.
Pneumococcal Conjugate Vaccines (PCVs)
Science And Technology Pneumococcal Conjugate Vaccines pneumonia meningitis sepsis
Pneumococcal Conjugate Vaccines: Protection & Mechanism
PCVs protect against Streptococcus pneumoniae bacteria causing pneumonia, meningitis, and sepsis
Introduced in India's Universal Immunization Programme in 2017
Can cause mild side effects like fever and irritability — no vaccine is side-effect free
Conjugate technology makes vaccines work better in infants under 2 years
Pneumococcal Conjugate Vaccines (PCVs) target Streptococcus pneumoniae, a deadly bacteria that kills more children under 5 than any other vaccine-preventable disease. The 'conjugate' technology attaches bacterial sugars to carrier proteins, making the vaccine effective even in infants whose immune systems can't recognize plain bacterial sugars.
Diseases Prevented by PCVs
Disease | What Happens | Age Group Most Affected | Mortality Risk |
|---|---|---|---|
Pneumonia | Lung infection, difficulty breathing | Children under 5 | High in developing countries |
Meningitis | Brain/spinal cord infection | Infants, young children | 10-15% mortality rate |
Sepsis | Blood poisoning, organ failure | All ages, especially infants | 20-50% mortality rate |
Otitis Media | Severe ear infection | Children 6 months - 2 years | Low mortality, hearing loss risk |
Why PCVs Matter in India
Pneumonia causes 16% of all child deaths in India — more than diarrhea or malaria
India has highest pneumonia burden globally with 4 lakh child deaths annually
Drug-resistant pneumococcus is rising — prevention better than treatment
Cost-effective: ₹1 spent on vaccination saves ₹3 in treatment costs
Trap: Statement 3 claims vaccines have 'no side effects' — all vaccines cause mild side effects
Confusion: PCVs prevent pneumonia only — they actually prevent pneumonia + meningitis + sepsis
Mix-up: Pneumococcal vs Meningococcal vaccines — different bacteria, different diseases
Vaccines & Antimicrobial Resistance
Science And Technology antibiotics drug resistant bacteria
How Vaccines Combat Antimicrobial Resistance (AMR)
Vaccines prevent infections → less antibiotic use → reduced resistance
PCVs can cut antibiotic use by up to 50% per year
India faces AMR crisis — vaccines are prevention strategy
Vaccine-AMR Prevention Chain
%%{init: {"flowchart": {"wrappingWidth": 460}}}%%
flowchart TD
s1["`**Bacterial Infection Occurs**
Streptococcus pneumoniae infects child`"]
s2["`**Antibiotic Treatment Given**
Doctors prescribe antibiotics to fight infection`"]
s3["`**Bacteria Develop Resistance**
Overuse creates drug-resistant strains`"]
s4["`**Vaccines Break the Chain**
Prevention eliminates need for antibiotics`"]
s5["`**Reduced AMR Development**
Less antibiotic pressure = slower resistance`"]
s1 --> s2
s2 --> s3
s3 --> s4
s4 --> s5India's AMR Crisis
Problem | Scale in India | Vaccine Solution |
|---|---|---|
Antibiotic Overuse | 70% antibiotics sold without prescription | Vaccines reduce infection → less antibiotic need |
Drug-Resistant TB | 1.3 lakh MDR-TB cases annually | BCG vaccine prevents initial TB infection |
Hospital Infections | 60-70% ICU infections are drug-resistant | Pneumococcal vaccines reduce hospital admissions |
Economic Cost | ₹73,000 crore annual AMR cost | Vaccination much cheaper than resistance treatment |
Logic: Vaccines don't directly kill resistant bacteria — they prevent infections so antibiotics aren't needed
Scope: AMR affects all bacteria, not just pneumococcus — but each vaccine helps with its target disease
Vaccine Safety & Side Effects
Science And Technology side effects allergic reactions
Vaccine Side Effects: Facts vs Myths
All vaccines cause mild side effects — fever, pain, irritability are normal
Serious side effects are extremely rare — 1 in million doses
Benefits far outweigh risks — vaccines prevent death and disability
PCV Side Effects Profile
Type | Frequency | Examples | Management |
|---|---|---|---|
Common (>10%) | Very frequent | Fever, injection site pain, irritability | Paracetamol, rest, normal in 1-2 days |
Uncommon (1-10%) | Less frequent | Loss of appetite, vomiting, rash | Symptomatic treatment, monitor |
Rare (<1%) | Very infrequent | High fever >39°C, persistent crying | Medical consultation needed |
Very Rare (<0.01%) | Extremely rare | Severe allergic reaction | Emergency treatment, hospitalization |
India's Vaccine Safety System
AEFI surveillance tracks all adverse events through digital platform
National AEFI Committee investigates serious cases within 48 hours
No-fault compensation for vaccine injury victims under new policy
Cold chain monitoring ensures vaccine quality from manufacture to delivery
Absolute claims: 'No side effects' or 'completely safe' are always false for any vaccine
Risk perception: People fear rare vaccine risks more than common disease risks
Causation vs correlation: Events after vaccination may not be caused by vaccination
India's Universal Immunization Programme
Science And Technology
PCVs in India's National Immunization Strategy
PCV introduced in UIP in 2017 after successful pilot studies
Mission Indradhanush boosted vaccination coverage from 65% to 85%
India manufactures Pneumosil — indigenous PCV reducing import dependence
UIP Vaccine Schedule for PCVs
Age | Dose | Vaccine Used | Coverage Status |
|---|---|---|---|
6 weeks | Primary dose 1 | PCV-13 (Pneumosil) | Rolled out in 5 states first |
10 weeks | Primary dose 2 | PCV-13 (Pneumosil) | Expanded to 8 states by 2018 |
14 weeks | Primary dose 3 | PCV-13 (Pneumosil) | National rollout by 2019 |
12-15 months | Booster dose | PCV-13 (Pneumosil) | Critical for long-term immunity |
Implementation Challenges
Cost barrier: PCVs are expensive — ₹3,000+ per child for full course
Cold chain: Requires 2-8°C storage in remote areas with poor electricity
Awareness gap: Parents don't understand pneumonia prevention vs treatment
Private market: Only 30% coverage — UIP expansion crucial for equity
India's Vaccine Ecosystem
# Universal Immunization Programme
## Manufacturing
- Serum Institute (Pneumosil)
- Bharat Biotech
- Indian Immunologicals
## Delivery
- ANMs at villages
- Primary Health Centers
- Private clinics
- Mission Indradhanush
## Monitoring
- Co-WIN platform
- AEFI surveillance
- Coverage surveys
- Disease surveillance